National Comprehensive Cancer Network

NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN ORP Grant History
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Updated Guidelines for Colon and Rectal Cancers

The NCCN Clinical Practice Guidelines in Oncology™ for Colon Cancer and for Rectal Cancer have been updated and published. Both Guidelines are now available in v.1.2010.

Several updates were made to the NCCN Guidelines for Colon Cancer and for Rectal Cancer based on BRAF gene status. Updates include a new section for BRAF testing added to the Principles of Pathologic Review. For patients with metastatic disease, consideration of tumor BRAF gene status was added to the workup recommendations as an option if KRAS is nonmutated. A new footnote was added stating that "Patients with a known V600E BRAF mutation appear to be unlikely to benefit from anti-EGFR monoclonal antibodies."